8
views
0
recommends
+1 Recommend
2 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Neutralisation Hierarchy of SARS-CoV-2 Variants of Concern Using Standardised, Quantitative Neutralisation Assays Reveals a Correlation With Disease Severity; Towards Deciphering Protective Antibody Thresholds

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The rise of SARS-CoV-2 variants has made the pursuit to define correlates of protection more troublesome, despite the availability of the World Health Organisation (WHO) International Standard for anti-SARS-CoV-2 Immunoglobulin sera, a key reagent used to standardise laboratory findings into an international unitage. Using pseudotyped virus, we examine the capacity of convalescent sera, from a well-defined cohort of healthcare workers (HCW) and Patients infected during the first wave from a national critical care centre in the UK to neutralise B.1.1.298, variants of interest (VOI) B.1.617.1 (Kappa), and four VOCs, B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma) and B.1.617.2 (Delta), including the B.1.617.2 K417N, informally known as Delta Plus. We utilised the WHO International Standard for anti-SARS-CoV-2 Immunoglobulin to report neutralisation antibody levels in International Units per mL. Our data demonstrate a significant reduction in the ability of first wave convalescent sera to neutralise the VOCs. Patients and HCWs with more severe COVID-19 were found to have higher antibody titres and to neutralise the VOCs more effectively than individuals with milder symptoms. Using an estimated threshold for 50% protection, 54 IU/mL, we found most asymptomatic and mild cases did not produce titres above this threshold.

          Related collections

          Most cited references62

          • Record: found
          • Abstract: found
          • Article: not found

          A Novel Coronavirus from Patients with Pneumonia in China, 2019

          Summary In December 2019, a cluster of patients with pneumonia of unknown cause was linked to a seafood wholesale market in Wuhan, China. A previously unknown betacoronavirus was discovered through the use of unbiased sequencing in samples from patients with pneumonia. Human airway epithelial cells were used to isolate a novel coronavirus, named 2019-nCoV, which formed a clade within the subgenus sarbecovirus, Orthocoronavirinae subfamily. Different from both MERS-CoV and SARS-CoV, 2019-nCoV is the seventh member of the family of coronaviruses that infect humans. Enhanced surveillance and further investigation are ongoing. (Funded by the National Key Research and Development Program of China and the National Major Project for Control and Prevention of Infectious Disease in China.)
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Fitting Linear Mixed-Effects Models Usinglme4

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              A novel coronavirus associated with severe acute respiratory syndrome.

              A worldwide outbreak of severe acute respiratory syndrome (SARS) has been associated with exposures originating from a single ill health care worker from Guangdong Province, China. We conducted studies to identify the etiologic agent of this outbreak. We received clinical specimens from patients in seven countries and tested them, using virus-isolation techniques, electron-microscopical and histologic studies, and molecular and serologic assays, in an attempt to identify a wide range of potential pathogens. None of the previously described respiratory pathogens were consistently identified. However, a novel coronavirus was isolated from patients who met the case definition of SARS. Cytopathological features were noted in Vero E6 cells inoculated with a throat-swab specimen. Electron-microscopical examination revealed ultrastructural features characteristic of coronaviruses. Immunohistochemical and immunofluorescence staining revealed reactivity with group I coronavirus polyclonal antibodies. Consensus coronavirus primers designed to amplify a fragment of the polymerase gene by reverse transcription-polymerase chain reaction (RT-PCR) were used to obtain a sequence that clearly identified the isolate as a unique coronavirus only distantly related to previously sequenced coronaviruses. With specific diagnostic RT-PCR primers we identified several identical nucleotide sequences in 12 patients from several locations, a finding consistent with a point-source outbreak. Indirect fluorescence antibody tests and enzyme-linked immunosorbent assays made with the new isolate have been used to demonstrate a virus-specific serologic response. This virus may never before have circulated in the U.S. population. A novel coronavirus is associated with this outbreak, and the evidence indicates that this virus has an etiologic role in SARS. Because of the death of Dr. Carlo Urbani, we propose that our first isolate be named the Urbani strain of SARS-associated coronavirus. Copyright 2003 Massachusetts Medical Society
                Bookmark

                Author and article information

                Contributors
                Journal
                Front Immunol
                Front Immunol
                Front. Immunol.
                Frontiers in Immunology
                Frontiers Media S.A.
                1664-3224
                07 March 2022
                2022
                07 March 2022
                : 13
                : 773982
                Affiliations
                [1] 1 Viral Pseudotype Unit, Medway School of Pharmacy, Universities of Kent & Greenwich , Chatham, United Kingdom
                [2] 2 Laboratory of Viral Zoonotics, Department of Veterinary Medicine, University of Cambridge , Cambridge, United Kingdom
                [3] 3 DIOSynVax, University of Cambridge , Cambridge, United Kingdom
                [4] 4 Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg , Regensburg, Germany
                [5] 5 Institute of Medical Microbiology and Hygiene, University of Regensburg , Regensburg, Germany
                [6] 6 Division of Virology, National Institute for Biological Standards and Control , Potters Bar, United Kingdom
                [7] 7 Royal Papworth Hospital NHS Foundation Trust , Cambridge, United Kingdom
                Author notes

                Edited by: Giulia Carla Marchetti, University of Milan, Italy

                Reviewed by: Daniele Focosi, Pisana University Hospital, Italy; Noah Sather, University of Washington, United States

                *Correspondence: Jonathan Heeney, Jlh66@ 123456cam.ac.uk ; Nigel Temperton, n.temperton@ 123456kent.ac.uk

                †These authors have contributed equally to this work

                This article was submitted to Viral Immunology, a section of the journal Frontiers in Immunology

                Article
                10.3389/fimmu.2022.773982
                8940306
                35330908
                b7f829d5-bd76-4a65-8f0b-9fa37891e7dc
                Copyright © 2022 Cantoni, Mayora-Neto, Nadesalingam, Wells, Carnell, Ohlendorf, Ferrari, Palmer, Chan, Smith, Bentley, Einhauser, Wagner, Page, Raddi, Baxendale, Castillo-Olivares, Heeney and Temperton

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 10 September 2021
                : 07 February 2022
                Page count
                Figures: 4, Tables: 4, Equations: 2, References: 67, Pages: 12, Words: 5734
                Funding
                Funded by: National Institute for Health Research , doi 10.13039/501100000272;
                Award ID: COV0170
                Categories
                Immunology
                Original Research

                Immunology
                covid-19,variants of concern,correlates of protection (cop),international standard,disease severity,20/136,iu/ml

                Comments

                Comment on this article